Patents by Inventor Liron Shemesh-Darvish

Liron Shemesh-Darvish has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BChE ALBUMIN FUSIONS FOR THE TREATMENT OF COCAINE ABUSE
    Publication number: 20140065126
    Abstract: A method of attenuating a biological effect of cocaine exposure in a primate. Such method includes administering to the primate an amount of a BChE-albumin fusion protein comprising the amino acid substitutions A227S, S315G, A356W, and Y360G, wherein the amount of the fusion protein is effective to cause attenuation of the biological effect of cocaine exposure in the primate.
    Type: Application
    Filed: September 4, 2013
    Publication date: March 6, 2014
    Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Liora Sklair-Tavron, Moti Rosenstock, Liron Shemesh-Darvish, Hussein Hallak, Victor Piryatinsky, Viktor Roschke, David Lafleur
  • BChE albumin fusions for the treatment of cocaine abuse
    Patent number: 8541373
    Abstract: A method of attenuating a biological effect of cocaine exposure in a primate. Such method includes administering to the primate an amount of a BChE-albumin fusion protein comprising the amino acid substitutions A227S, S315G, A356W, and Y360G, wherein the amount of the fusion protein is effective to cause attenuation of the biological effect of cocaine exposure in the primate.
    Type: Grant
    Filed: December 7, 2010
    Date of Patent: September 24, 2013
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Liora Sklair-Tavron, Moti Rosenstock, Liron Shemesh-Darvish, Hussein Hallak, Victor Piryatinsky, Viktor Roschke, David Lafleur
  • BChE ALBUMIN FUSIONS FOR THE TREATMENT OF COCAINE ABUSE
    Publication number: 20110312900
    Abstract: A method of attenuating a biological effect of cocaine exposure in a primate. Such method includes administering to the primate an amount of a BChE-albumin fusion protein comprising the amino acid substitutions A227S, S315G, A356W, and Y360G, wherein the amount of the fusion protein is effective to cause attenuation of the biological effect of cocaine exposure in the primate.
    Type: Application
    Filed: December 7, 2010
    Publication date: December 22, 2011
    Inventors: Liora Sklair-Tavron, Moti Rosenstock, Liron Shemesh-Darvish, Hussein Hallak, Victor Piryatinsky, Viktor Roschke, David Lafleur